Treatment of HIV disease in the new millennium.

Highly active antiretroviral therapy (HAART), which typically consists of 3-drug combinations of antiretroviral agents, has decreased dramatically the incidence of AIDS and death among HIV-infected persons in the United States. HIV infection no longer is viewed as a death sentence. Complete suppression of viral replication through the use of HAART can reverse the immune deficits formerly thought to be inevitable. However, drug toxicity, cross-resistance, and less-than-perfect adherence to prescribed antiretroviral regimens make the medical management of the HIV-infected person complex. An overview of the current approach to antiretroviral therapy is presented in this article.

[1]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[2]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[3]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[4]  L. Kalish,et al.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. , 1999, The New England journal of medicine.

[5]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[6]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.

[7]  J. Karon,et al.  Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial , 1999, The Lancet.

[8]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[9]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[10]  Julio S. G. Montaner,et al.  Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.

[11]  D. van Strijp,et al.  The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? , 1994, Virology.

[12]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[13]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[14]  J. Gerberding.  Management of occupational exposures to blood-borne viruses. , 1995, The New England journal of medicine.